Center Hospitalier Of Versailles
Center Hospitalier Of Versailles
Institute Pasteur Paris, University Paris - Sud, Center Hospitalier Of Versailles and Assistance Publique Hopitaux De Paris | Date: 2015-04-01
The present invention relates to the field of Clostridium difficile infections. Methods of diagnosing, treating and preventing Clostridium difficile-associated disease and recurrent CDAD are disclosed herein.
Institute Pasteur Paris, University Paris - Sud and Center Hospitalier Of Versailles | Date: 2017-02-08
The present invention relates to the field of Clostridium difficileinfections. Methods of diagnosing, treating and preventing Clostridium difficile-associated disease and recurrent CDAD are disclosed herein.
Dommergues M.-A.,Center Hospitalier Of Versailles
Medecine Therapeutique Pediatrie | Year: 2016
Vaccinating women during pregnancy could be ideal to ensure the indirect protection of newborns and infants through their mother's antibodies. Influenza is an important cause of morbidity and mortality among pregnant women and young infants, and influenza infection during pregnancy has also been associated with adverse obstetric and birth outcomes (preterm birth, low birth weight). There is substantial evidence - from randomized trials and observational studies - that maternal influenza immunization can protect pregnant women and their infants from influenza disease. In addition, there is compelling observational evidence that prevention of influenza in pregnant women can also protect against certain adverse pregnancy outcomes, including stillbirth and preterm birth. Data collected following the use of inactivated influenza vaccines - the only vaccines recommended to French pregnant women - did not show any specific risk for pregnant women and fetuses. Despite the recommendations, very few women receive this vaccine in France. Pertussis has the highest disease burden in infants younger than 3 months. As pertussis vaccines are licensed for use only after 6 weeks of age, additional preventive strategies are required for the very young. Efficient cocooning strategies are difficult to implement and the results of this strategy are not optimal. In contrast, pertussis antibodies of maternal origin are readily transferred to the fetus. Vaccination against pertussis is not yet recommended for French pregnant women. Over the past three years, several countries such as the United States and the United Kingdom decided to introduce a pertussis booster vaccine for pregnant women. Data from the British experience indicated that vaccine effectiveness for the maternal programme remained at around 90%, where the vaccine is provided at least 1 week prior to delivery, and that this vaccination strategy is both safe. More studies are needed to fully characterize the optimal timing of maternal immunization and to evaluate the possible blunting effect of maternal immunization with the infant pertussis immune response. © 2017 John Libbey Eurotext.
Le Boeuf D.,Center Hospitalier Of Versailles
Soins | Year: 2016
The implementation of telemedicine has drawn on numerous innovative initiatives and has required a legal framework to be established. Today, the various uses of this valuable 'connected tool' can be appropriated in order to improve access to care. It also improves cooperation between healthcare professionals scattered across the health region. © 2016 Elsevier Masson SAS.
Le Boeuf D.,Center Hospitalier Of Versailles
Soins | Year: 2017
The French inter-ministerial mission for the fight against drugs and addictive behaviour (MILDECA) is responsible for coordinating the campaign against drugs and addictive practices. Thanks to a medical concept of these phenomena which has evolved towards a very broad definition of ĝ addictive practices', public policies are increasingly orientated towards prevention and health education. Specific structures and tools are available to health professionals to help improve their knowledge and the provision of care in this field. © 2017 Elsevier Masson SAS.
Bruneel F.,Center Hospitalier Of Versailles
Reanimation | Year: 2012
Artesunate, a semi-synthetic derivative of artemisinin, has proven to be an efficient therapy for severe malaria. In endemic areas, the findings clearly support the superiority of intravenous artesunate over quinine for the treatment of severe malaria in both adults and children. In France, artesunate is available since May 2011. This review describes the history of artesunate, reports the major studies supporting the superiority of artesunate over quinine, details the use of artesunate in France and Europe, and describes the prescription practices and monitoring of artesunate. © SRLF et Springer-Verlag 2011.
Hentgen V.,Center Hospitalier Of Versailles |
Grateau G.,Hopital Tenon |
Stankovic-Stojanovic K.,Hopital Tenon |
Amselem S.,French Institute of Health and Medical Research |
Jeru I.,French Institute of Health and Medical Research
Arthritis and Rheumatism | Year: 2013
Objective Familial Mediterranean fever (FMF) is an autosomal-recessive autoinflammatory disease due to mutations in MEFV. Descriptions of disease manifestations among patients carrying a single mutated MEFV allele are becoming more frequent, although no data are available on the long-term outcome. We undertook this study to assess the accuracy of clinical diagnosis in children carrying a single mutated MEFV allele with symptoms of recurrent autoinflammatory disorder. Methods We performed a retrospective single-center study of 33 patients with autoinflammatory disorders age <6 years at disease onset with 1 mutated MEFV allele. The phenotype of the patients was investigated in detail, and the clinical picture and outcome of 18 patients with an initial FMF diagnosis according to current clinical criteria were compared to those of 25 homozygous or compound heterozygous FMF patients. Results No major differences in presenting signs or initial response to colchicine were observed between patient groups. During followup, heterozygotes had a milder disease course compared to homozygotes and were less prone than homozygotes to experience new clinical signs of FMF. At puberty, clinical signs of FMF completely disappeared in 5 of 18 heterozygotes, allowing them to discontinue colchicine without recurrence of symptoms or increases in inflammatory marker levels. Conclusion Our data suggest that the clinical diagnosis of FMF in very young heterozygous children should be made with caution. At this young age they can present with an FMF-like disease - similar to that seen in patients carrying 2 mutated alleles - that is not necessarily predictive of life-long illness. Copyright © 2013 by the American College of Rheumatology.
Dommergues M.-A.,Center Hospitalier Of Versailles |
Hentgen V.,Center Hospitalier Of Versailles
Scandinavian Journal of Infectious Diseases | Year: 2012
Background: Antibiotic consumption is one of the main causes of bacterial resistance to antibiotics and a major public health problem worldwide, especially in France. A national campaign was implemented in 2001 to reduce the inappropriate use of antibiotics in France, and guidelines for the management of respiratory tract infections were published in 2005. Methods: In this study, data on paediatric outpatient antibiotic use in France between 2000 and 2010 were derived from prescribing panels of the Permanent Survey of Medical Prescription, which analyzed prescriptions by 835 French general practitioners and specialists. Results: Overall, antibiotic prescriptions decreased by 57.2% between 2001 and 2010 in children aged 024 months, by 50.0% in children aged 25 months to 6 y, and by 45.8% in children older than 6 y of age. In the 3 age groups, the greatest reduction was for rhinopharyngitis (83.4%) and the lowest was for otitis (22.4%). Because otitis is one of the most common diseases in childhood, the proportion of antibiotic prescriptions due to otitis in children aged 024 months consequently increased from 22.5% in 2000 to 42.3% in 2010. Conclusion: Additional measures may be necessary to decrease antibiotic consumption related to otitis in young children. © 2012 Informa Healthcare.
Mornet E.,Center Hospitalier Of Versailles
Sub-Cellular Biochemistry | Year: 2015
Hypophosphatasia (HPP) is due to deficient activity of the tissue-nonspecific isoenzyme of alkaline phosphatase (TNAP). This enzyme cleaves extracellular substrates inorganic pyrophosphates (PPi), pyridoxal-5′- phosphate (PLP), phosphoethanolamine (PEA) and nucleotides, and probably other substrates not yet identified. During the last 15 years the role of TNAP in mineralization, and to a less degree in brain, has been investigated, providing hypotheses and explanations for both bone and neuronal HPP phenotypes. ALPL, the gene encoding TNAP, is subject to many mutations, mostly missense mutations. A few number of mutations are recurrently found and may be quite frequent in particular populations. This reflects founder effects. The great variety of mutations results in a great number of compound heterozygous genotypes and in highly variable clinical expressivity. A good correlation was observed between the severity of the disease and in vitro enzymatic activity of the mutant protein measured after site-directed mutagenesis. Many missense mutations found in severe hypophosphatasia produced a mutant protein that failed to reach the cell membrane, was accumulated in the cis-Golgi and was subsequently degraded in the proteasome. Missense mutations located in the catalytic site or in the homodimer interface were often shown by site-directed mutagenesis to have a dominant negative effect. Currently molecular diagnosis of HPP is based on the sequencing of the coding sequence of ALPL that allows detection of approximately 95 % of mutations in severe cases. In addition, other genes, especially genes encoding proteins involved in the regulation of extracellular PPi concentration, could modify the phenotype (modifier genes). © Springer Science+Business Media Dordrecht 2015.
Panel P.,Center Hospitalier Of Versailles |
Grosdemouge I.,Center Hospitalier Of Versailles
Fertility and Sterility | Year: 2010
Objective: To assess a new hysteroscopic method of tubal sterilization; specifically, to examine the factors associated with placement failure of Essure® implants. Design: Observational, multicenter, 6-month study. Setting: Seven gynecology clinics, including five public hospitals and two private clinics, in France. Patient(s): A total of 495 women who provided informed consent. Intervention(s): All procedures were done by a vaginoscopic approach with a 5-mm operating hysteroscope. Main Outcome Measure(s): Data collected were age, parity, type of anesthesia, premedication, endometrial aspect, ostia visualization, duration of the procedure, pain during the procedure, and associated procedures. Unilateral and bilateral placement rates were assessed. Adverse events at 3 months (expulsion, migration, perforation) were also recorded. Result(s): Mean parity was 2.45; 20 women were nulliparous. In 56.3% of cases (n = 277), none or local anesthesia was used for the placement procedure. Overall, 86% of the women (n = 423) had nonsteroidal anti-inflammatory drug (NSAID) premedication, and 8.1% (n = 40) had another intrauterine surgical procedure performed at the same time. In 24 cases, at least one of the tubal ostia could not be visualized well during hysteroscopy. Conclusion(s): The failure rate for Essure® micro-insert placement was 6% at first attempt and 3.3% after two attempts. Success rate was not significantly associated with parity, mode of analgesia, NSAID premedication, or combination with another procedure. The only factor significantly associated with the failure rate was poor visualization of the tubal ostia. © 2010 American Society for Reproductive Medicine.